12:00 AM
 | 
Jan 25, 2016
 |  BC Week In Review  |  Company News  |  Deals

Promiliad, Spero Therapeutics, University of Connecticut deal

Promiliad granted Spero a worldwide, exclusive sublicense to develop and commercialize dihydrofolate reductase (DHFR) inhibitors that target Gram-positive and -negative bacteria, fungi and protists. According to Spero, Promiliad...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >